TP-03 + TP-03 Vehicle

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Blepharitis

Conditions

Blepharitis

Trial Timeline

Apr 29, 2021 → May 9, 2022

NCT ID

NCT04784091

About TP-03 + TP-03 Vehicle

TP-03 + TP-03 Vehicle is a phase 3 stage product being developed by Tarsus Pharmaceuticals for Blepharitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04784091. Target conditions include Blepharitis.

What happened to similar drugs?

5 of 9 similar drugs in Blepharitis were approved

Approved (5) Terminated (1) Active (3)

✅Lotilaner ophthalmic solution, 0.25% + Vehicle controlTarsus PharmaceuticalsApproved

🔄Lotilaner + Vehicle ControlLianBioPhase 3

🔄ISV-305Sun PharmaceuticalPhase 3

🔄ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + DexamethasoneSun PharmaceuticalPhase 3

✅AzaSite®MerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05454956	Phase 2	Completed	Aug 3, 2022	May 18, 2023	Meibomian Gland Dysfunction
NCT04784091	Phase 3	Completed	Apr 29, 2021	May 9, 2022	Blepharitis

Competing Products

15 competing products in Blepharitis

See all competitors

Product	Company	Stage	Hype Score
Lotilaner ophthalmic solution, 0.25% + Vehicle control	Tarsus Pharmaceuticals	Approved	37
TP-03, 0.25% + TP-03 Vehicle	Tarsus Pharmaceuticals	Phase 2/3	32
Lotilaner + Vehicle Control	LianBio	Phase 3	30
ISV-305	Sun Pharmaceutical	Phase 3	40
ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + Dexamethasone	Sun Pharmaceutical	Phase 3	40
AzaSite®	Merck	Approved	43
AzaSite®	Merck	Approved	43
AzaSite®	Merck	Approved	43
Azithromycin ophthalmic solution, 1% + Placebo	Merck	Phase 2	35
AzaSite®	Merck	Approved	43
Azithromycin ophthalmic solution, 1% + Placebo	Merck	Phase 2	35
Azithromycin ophthalmic solution, 1% + Vehicle	Merck	Phase 2	27
Pimecrolimus 0.3% Ophthalmic Ointment + Placebo Ophthalmic Ointment	Viatris	Phase 3	29
GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID	Glaukos	Phase 2	39
KPI-121 + Vehicle	Kala Pharmaceuticals	Phase 2	25